12 Other operating income/expenses

 

 

 

€ million

2018

2017

Provisions

-19

5

Impairment trade receivable

-4

-4

Loss on disposal of non-current assets

-7

-1

Reimbursement by third parties for development expenses

1

8

Grants received

15

14

Collaboration agreement for the development and commercialization of Evenity™

-10

-39

Other income/expenses (-)

0

6

Total other operating income/expenses (-)

-24

-11

 

 

 

The result of the collaboration agreement with Amgen for the development and commercialization of Evenity™ amounted to € -10 million expenses (compared to € -39 million in 2017). All recharges of development and commercialization expenses to/from Amgen are classified as other operating income/expenses. The equivalent total net recharges as per 31 December 2018 consisted of € 2 million marketing and selling income (€ -17 million in 2017) and € -12 million development expenses (€ -22 million in 2017).

The provisions are mainly related to VAT risks and grant recoverability risks.